Second-line and beyond in mCRC: Optimising the benefit and reducing the risk

Bookmark and Share
Published: 9 May 2019
Views: 550
Prof Mohamed Salem - Georgetown University Hospital, Washington D.C., USA

Prof Mohamed Salem speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the
recent advances in the treatment of metastatic colon cancer in the second-line setting and beyond.

Despite numerous clinical trials in the past, Prof Salem acknowledges the fact these trials have not shown any clinical benefit thus far.

However, he discusses the positive results achieved from several clinical trials, including the addition of regorafenib to oxaliplatin or irinotecan and the use of TAS-102 in this setting.

Prof Salem also notes the increased understanding of the biology of colorectal cancer as a recent major advancement - as oncologists can now differentiate between different types of the disease.

He believes that this field is moving towards precision medicine, with the help of recent advances in genetic testing.